Indian J Pharm Close
 

Figure 3: Survival by grouping Group I survival: 35.53% (SE - 11.52%); mean survival 65.71 months (±17.95, 95% CI 30.53-100.90 months). Group II survival: 68.57% (SE - 18.63%); mean survival 110.03 months (±27.15, 95% CI 56.81-163.25). Difference in survival between groups I and II was statistically significant (P = 0.0012). Groups III and IV had no mortality. The solitary event in group IV was a loss to follow-up.

Figure 3: Survival by grouping Group I survival: 35.53% (SE - 11.52%); mean survival 65.71 months (±17.95, 95% CI 30.53-100.90 months). Group II survival: 68.57% (SE - 18.63%); mean survival 110.03 months (±27.15, 95% CI 56.81-163.25). Difference in survival between groups I and II was statistically significant (P = 0.0012). Groups III and IV had no mortality. The solitary event in group IV was a loss to follow-up.